IP Library Patent Application 13310359
Patent Application
App. No. 13/310,359

Nitric Oxide Treatments

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/310,359
Abstract

Portable and pure nitric oxide delivery systems can be used to treat a variety of patient conditions.

Claims (61)

1 . A method of treating a patient after cardiopulmonary resuscitation has been performed on the patient comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

2 . The method of claim 1 , wherein the system includes a cartridge including a surface-activated material and a reducing agent.

3 . The method of claim 2 , wherein the reducing agent includes an antioxidant.

4 . The method of claim 3 , wherein the antioxidant is ascorbic acid, alpha tocopherol, or gamma tocopherol.

5 . The method of claim 2 , wherein the surface-activated material includes a silica gel.

6 . The method of claim 1 , wherein nitric oxide is delivered to a patient between about 15 minutes and about 3 hours after cardiopulmonary resuscitation has been performed on the patient.

7 . The method of claim 6 , wherein nitric oxide is delivered to a patient between about 45 minutes and about 1.25 hours after cardiopulmonary resuscitation has been performed on the patient.

8 . The method of claim 1 , wherein nitric oxide is delivered to the patient for a period between 15 minutes and 48 hours.

9 . The method of claim 8 , wherein nitric oxide is delivered to the patient for a period between 12 hours and 36 hours.

10 . The method of claim 8 , wherein the nitric oxide is delivered to a patient continuously.

11 . The method of claim 8 , wherein the nitric oxide is delivered to a patient intermittently.

12 . The method of claim 1 , further comprising releasing nitrogen dioxide from a nitrogen dioxide source.

13 . The method of claim 12 , wherein the nitrogen dioxide source is coupled to the cartridge.

14 . The method of claims 13 , wherein the nitrogen dioxide source includes a nitrogen dioxide gas bottle.

15 . The method of claim 12 , wherein the nitrogen dioxide source includes a reservoir including liquid dinitrogen tetroxide.

16 . The method of claim 1 , wherein the cartridge includes a plurality of cartridges.

17 . A method of treating a patient after the patient has experienced an event resulting in inflammation in the central nervous system comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

18 . The method of claim 17 , wherein the event resulting in inflammation in the central nervous system includes a stroke or spinal cord injury.

19 . The method of claim 17 , wherein the system includes a cartridge including a surface-activated material and a reducing agent.

20 . A method of treating a patient having sleep apnea comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

21 . The method of claim 20 , wherein delivering nitric oxide includes supplying forced air into the patient.

22 . A method of treating a patient having pulmonary arterial hypertension comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

23 . The method of claim 22 , further comprising delivering a PDE5 inhibitor to the patient.

24 . A method of treating a patient having a pulmonary disorder comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

25 . The method of claim 24 , wherein the pulmonary disorder is pulmonary hypertension, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, acute chest syndrome, infectious lung disease, hypoxemia, respiratory failure, respiratory distress syndrome, pulmonary embolism, cystic fibrosis, or combinations thereof.

26 . A method of treating a patient having a cardiac or blood disorder comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

27 . The method of claim 26 , wherein the blood disorder is sickle cell.

28 . The method of claim 26 , wherein the cardiac disorder includes heart failure or cardiovascular shock.

29 . A method of treating a patient having a kidney disorder comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

30 . The method of claim 29 , wherein the kidney disorder includes alpha-1-adrenoreceptor in vasoreactivity.

31 . A method of treating a patient who is attempting to quit smoking comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

32 . A method of treating a patient having a neurologic disorder comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

33 . A method of treating a patient comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

delivering an effective concentration of the nitric oxide to the patient.

34 . The method of claim 33 , wherein the patient is postoperative.

35 . The method of claim 33 , wherein the postoperative patient experienced pulmonary or cardiac stress.

36 . The method of claim 33 , wherein the patient experienced ischemic injury or reperfusion injury.

37 . The method of claim 33 , wherein the patient experienced organ failure.

38 . The method of claim 33 , wherein the patient has altitude illness or pulmonary adema.

39 . A method of treating a patient having a wound comprising:

passing nitrogen dioxide through a system configured to convert the nitrogen dioxide into nitric oxide; and

exposing the wound to an effective concentration of the nitric oxide.

Assignments (5)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Aug 7, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 048173/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2011
From: FINE, DAVID H.; ROSCIGNO, ROBERT F.; VASQUEZ, GREGORY; JOHNSON, BRYAN; DENTON, RYAN
To: GENO LLC
Reel/Frame 027465/0860 →